5 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
rights that are important to our business; the fact that Fortress Biotech, Inc. controls a majority of the voting power of our outstanding capital stock
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
. controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants annually; and those risks
Why Avenue Therapeutics (ATXI) Shares Are Getting Hammered
ATXI
24 Apr 24
of its common stock, effective April 26. This decision, approved by the company’s Board of Directors and a majority of stockholders, aims to meet
Avenue Therapeutics Announces Reverse Stock Split
ATXI
FBIO
24 Apr 24
. controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants annually; our current
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
that are important to our business; the fact that Fortress Biotech, Inc. controls a majority of the voting power of our outstanding capital stock and has
- Prev
- 1
- Next